Wednesday, May 17, 2006

Pro-Life Groups Renew Call to Pull Abortion Drug RU 486

Women seeking elective chemical abortions remain at risk with RU-486 on the market, a U.S. bishops' aide told a government workshop convened in the wake of deaths from the drug.

Deirdre McQuade, a spokeswoman at the bishops' Secretariat for Pro-Life Activities, made her comment Thursday during a public meeting held by the U.S. Food and Drug Administration on RU-486, also known as Mifeprex.

The meeting was co-sponsored by the Centers for Disease Control and the National Institutes of Health. It was convened in response to the death of five women who have died from infections after undergoing RU-486 abortions.

McQuade said: "We continue to call for the passage of Holly's Law to temporarily suspend FDA approval of RU-486 while its approval process is reviewed."

"Holly's Law," as a U.S. House bill is known, is named after Holly Patterson, a California woman who died from septic shock after undergoing an RU-486 abortion.

"The CDC workshop is a constructive step," McQuade said, "but no substitute for the provisions in Holly's Law, as it neither addresses the distinct risks posed by RU-486 nor offers any immediate protection of women's lives."



Post a Comment

Links to this post:

Create a Link

<< Home